MacroGenics Inc (MGNX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
MacroGenics Inc stock (MGNX) is currently trading at $2.73. MacroGenics Inc PS ratio (Price-to-Sales) is 1.24. Analyst consensus price target for MGNX is $3.60. WallStSmart rates MGNX as Sell.
- MGNX PE ratio analysis and historical PE chart
- MGNX PS ratio (Price-to-Sales) history and trend
- MGNX intrinsic value — DCF, Graham Number, EPV models
- MGNX stock price prediction 2025 2026 2027 2028 2029 2030
- MGNX fair value vs current price
- MGNX insider transactions and insider buying
- Is MGNX undervalued or overvalued?
- MacroGenics Inc financial analysis — revenue, earnings, cash flow
- MGNX Piotroski F-Score and Altman Z-Score
- MGNX analyst price target and Smart Rating
MacroGenics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
MacroGenics Inc (MGNX) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in peg ratio, price/sales, revenue growth. Concerns around market cap and return on equity. Mixed signals suggest waiting for clearer direction before acting.
MacroGenics Inc (MGNX) Key Strengths (4)
Growing significantly faster than its price suggests
Revenue surging 113.00% year-over-year
Paying $1.24 for every $1 of annual revenue
64.58% held by institutions, strong professional interest
Supporting Valuation Data
MacroGenics Inc (MGNX) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Earnings declining -70.40%, profits shrinking
Company is losing money with a negative profit margin
Micro-cap company with very limited liquidity and high volatility
Premium pricing at 3.3x book value
Supporting Valuation Data
MacroGenics Inc (MGNX) Detailed Analysis Report
Overall Assessment
This company scores 43/100 in our Smart Analysis, earning a D grade. Out of 10 metrics analyzed, 4 register as strengths (avg 9.0/10) while 6 fall into concern territory (avg 1.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on PEG Ratio, Revenue Growth, Price/Sales. Valuation metrics including PEG Ratio (0.01), Price/Sales (1.24) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 113.00%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, EPS Growth. Some valuation metrics including Price/Book (3.27) suggest expensive pricing. Growth concerns include EPS Growth at -70.40%, which may limit upside. Profitability pressure is visible in Return on Equity at -87.00%, Operating Margin at -29.30%, Profit Margin at -49.90%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -87.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 113.00% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
MGNX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
MGNX's Price-to-Sales ratio of 1.24x trades at a deep discount to its historical average of 13.95x (11th percentile). The current valuation is 98% below its historical high of 50.32x set in Jul 2015, and 143% above its historical low of 0.51x in Jun 2025. Over the past 12 months, the PS ratio has expanded from ~0.5x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for MacroGenics Inc (MGNX) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
MacroGenics Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 150M with 113% growth year-over-year. The company is currently unprofitable, posting a -49.9% profit margin.
Key Findings
Revenue growing at 113% YoY, reaching 150M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Generating 43M in free cash flow and 43M in operating cash flow. Earnings are translating into actual cash generation.
The company is unprofitable with a -49.9% profit margin. The path to breakeven will be the key catalyst.
Earnings fell 70% YoY while revenue grew 113%. This gap usually reflects one-time items (tax benefits, write-offs) in the prior period, not an operational decline.
What to Watch Next
Growth sustainability: can MacroGenics Inc maintain 113%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact MacroGenics Inc.
Bottom Line
MacroGenics Inc is a high-conviction growth story with revenue accelerating at 113% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -49.9% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(70 last 3 months)
Data sourced from SEC Form 4 filings
Last updated: 8:28:09 AM
About MacroGenics Inc(MGNX)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapies to treat cancer in the United States. The company is headquartered in Rockville, Maryland.